This inventor holds 4 USPTO granted patents and 13 EPO patents. Top assignees: Oki Electric Industry Co., Ltd., Asubio Pharma Co. Ltd., Daiichi Suntory Pharma Co., Ltd.. Active years: 1989-2009.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1989-2009
Title: Innovations by Naohiro Watanabe
Introduction
Naohiro Watanabe is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of medicine, particularly in the treatment of dermatitis. With a total of four patents to his name, Watanabe's work has garnered attention for its innovative approaches to complex medical conditions.
Latest Patents
Watanabe's latest patents include a method of treating dermatitis that involves administering a chymase inhibitor. This method specifically targets dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen. The patents also disclose the use of quinazolidone derivatives of defined formulas for effective treatment. Another significant patent focuses on a chymase inhibitor for the treatment of eosinophilia, showcasing his commitment to advancing medical therapies.
Career Highlights
Throughout his career, Watanabe has worked with prominent companies such as Oki Electric Industry Co., Ltd. and Daiichi Suntory Pharma Co., Ltd. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to the advancement of medical science.
Collaborations
Watanabe has collaborated with esteemed colleagues, including Shunji Sakai and Tohru Kitagawa. These partnerships have played a crucial role in the development of his patents and the successful implementation of his research.
Conclusion
Naohiro Watanabe's contributions to the field of medicine through his innovative patents highlight his expertise and dedication. His work continues to influence the treatment of dermatitis and related conditions, making a significant impact in the medical community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile